不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
EBV+淋巴增殖性疾病：利用 EBV 作为治疗靶点的机会
英文原题：EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target.
查看英文原题
EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
EBV是一种普遍存在的人类肿瘤病毒，可导致淋巴增殖性疾病的发生，尤其是在免疫功能受损的患者中最为显著。EBV相关淋巴增殖性疾病的特征是潜伏EBV蛋白的表达，其严重程度从相对良性的增殖性反应到侵袭性恶性淋巴瘤不等。EBV的存在也可作为定向治疗EBV淋巴增殖性疾病的独特靶点，包括基于T细胞的免疫治疗。在这篇综述中，我们描述了EBV相关淋巴增殖性疾病，并特别关注靶向EBV的治疗方法。
展开英文摘要原文
Epstein-Barr virus (EBV) is a ubiquitous human tumor virus, which contributes to the development of lymphoproliferative disease, most notably in patients with impaired immunity. EBV-associated lymphoproliferation is characterized by expression of latent EBV proteins and ranges in severity from a relatively benign proliferative response to aggressive malignant lymphomas.
The presence of EBV can also serve as a unique target for directed therapies for the treatment of EBV lymphoproliferative diseases, including T cell-based immune therapies. In this review, we describe the EBV-associated lymphoproliferative diseases and particularly focus on the therapies that target EBV.
论文信息
- 作者
- Toner K、Bollard CM
- 单位
- Center for Cancer and Immunology Research.
- 文献类型
- 美国 NIH 资助研究 · 非美国政府资助研究 · 综述
- 期刊
- Blood2022 Feb 17
- 原文标识
- PubMed 34437680 · DOI 10.1182/blood.2020005466
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →